Thus, PSMA-PET can be used for a wide variety of purposes in prostate cancer patients, from initial staging and detection of recurrence, to pre-treatment evaluation of PSMA-targeted radionuclide therapy using [177Lu]Lu-/[225Ac]Ac-PSMA-617. The gene discussed is FOLH1; the disease is prostate cancer.